Ignite Creation Date:
2024-05-06 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03439046
Status:
COMPLETED
Last Update Posted:
2024-02-23
First Post:
2018-01-29
Brief Title:
Study of the Molecular Features of Postmenopausal Women With HR HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and in Patients With a PIK3CA Mutation on Second-line Treatment With Alpelisib Plus Fulvestrant
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-12-11
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-29
First Submit QC Date:
February 13 2018
Study First Post Date:
2018-02-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-31
Last Update Post Date:
2024-02-23
Last Update Post Date Type:
ACTUAL